Research Lead - DMPK

Req ID:  152316
Location: 

Saffron Walden, GB, CB10 1XL US Montreal (Senneville), Quebec, CA, H9X 3R3 Ashland, OH, US, 44805 Mattawan, MI, US, 49071 Wilmington, MA, US, 01887

For 70 years, Charles River employees have worked together to assist in the discovery, development and safe manufacture of new drug therapies. When you join our family, you will have a significant impact on the health and well-being of people across the globe. Whether your background is in life sciences, finance, IT, sales or another area, your skills will play an important role in the work we perform. In return, we’ll help you build a career that you can feel passionate about.

Job Summary

BASIC SUMMARY:  

As part of our continued success, we are looking for a Discipline Lead, DMPK to support both multidisciplinary and stand-alone ADME programs executed by our UK Early Discovery function. In this client facing, scientific leadership role your main responsibility will be to provide expert DMPK support to multidisciplinary integrated Drug Discovery projects, defining and implementing the DMPK strategy to expedite project progression. This is an opportunity to be part of an evolving team, at the forefront of Drug Discovery, combining experimental laboratory based ADME/DMPK sciences with informatics, in vitro and in vivo pharmacology and medicinal chemistry capability, in a pioneering commercial environment. Hybrid and remote working options that suit you can be discussed. 

Main Responsibilities:
•    To provide ADME/DMPK expertise, to drug discovery projects, integrating in vitro and in vivo data to help define project strategy and deliver agreed project objectives.
•    To contribute to Business Development activities (e.g. proposal preparation, discussions with potential clients).
•    To provide scientific leadership within the department, including proactively influencing the departments scientific direction and developing optimised processes to improve effectiveness.
•    To develop others through coaching, mentoring and motivate others to fulfil their potential. 
•    To embrace change and be a role model to maintain a high preforming team.
•    A demonstrated record of delivering DMPK and PK/PD expertise, including human PK and dose prediction, to projects with the ability to successfully troubleshoot scientific related issues.
•    Demonstrated impact on multiple drug discovery projects through to candidate selection, defining project direction and strategy.
•    To be an effective team player; with the confidence to stand up for what you believe in whilst listening to others to collaborate effectively with your peers.
•    An interest in new technologies and approaches, a willingness to innovate and help define the future direction of the department.
•    An understanding of the importance of identifying and implementing efficiencies to help us deliver the right data at the right time.
•    The ability to make effective decisions to positively impact project and departmental goals.

 
In return, you will have the opportunity to:
•    Be part of a rapidly developing, multi-disciplinary team who are
o    dedicated to partnering with our clients to develop quality candidate molecules
o    supportive of each other every step of the way
•    Be involved in the early stage drug discovery processing return, you will have the opportunity to: 
•    Be part of a multi-disciplinary team who are dedicated to partnering with our clients to discover quality candidate molecules 
•    Supportive of each other every step of the way
•    A total reward package that includes the opportunity for hybrid and flexible working, generous company pension contributions and the option for private medical and dental insurance.  Full relocation assistance is available for the right candidate.

Profile and Requirements

About Discovery
Discovery from Charles River is industry-proven in the successful development of novel therapies, with over 350 patents and 80 preclinical drug candidates delivered to our sponsors in the past 17 years. Backed by more than 650 scientists, our comprehensive, integrated portfolio employs the latest technology and platforms to provide chemistry, biology, and pharmacology services that support clients from the earliest stages of hit identification all the way through to IND. Our client-focused, collaborative approach creates true partnerships that anticipate challenges, overcome obstacles, and move us forward together on the journey of getting new drugs to market.

 

About Charles River
Charles River is an early-stage contract research organization (CRO). We have built upon our foundation of laboratory animal medicine and science to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, to support clients from target identification through preclinical development. Charles River also provides a suite of products and services to support our clients’ clinical laboratory testing needs and manufacturing activities. Utilizing this broad portfolio of products and services enables our clients to create a more flexible drug development model, which reduces their costs, enhances their productivity and effectiveness to increase speed to market.

 

With over 17,000 employees within 90 facilities in 20 countries around the globe, we are strategically positioned to coordinate worldwide resources and apply multidisciplinary perspectives in resolving our client’s unique challenges. Our client base includes global pharmaceutical companies, biotechnology companies, government agencies and hospitals and academic institutions around the world. And in 2019, revenue increased to $2.62 billion.

 

At Charles River, we are passionate about our role in improving the quality of people’s lives. Our mission, our excellent science and our strong sense of purpose guide us in all that we do, and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe. We have proudly supported the development of ~85% of the drugs approved by the FDA in 2019.